ATE425177T1 - Reduziertes fk228 und seine verwendung - Google Patents

Reduziertes fk228 und seine verwendung

Info

Publication number
ATE425177T1
ATE425177T1 AT01947940T AT01947940T ATE425177T1 AT E425177 T1 ATE425177 T1 AT E425177T1 AT 01947940 T AT01947940 T AT 01947940T AT 01947940 T AT01947940 T AT 01947940T AT E425177 T1 ATE425177 T1 AT E425177T1
Authority
AT
Austria
Prior art keywords
reduced
salt
compound
histone deacetylase
diseases
Prior art date
Application number
AT01947940T
Other languages
English (en)
Inventor
Hidenori Nakajima
Akito Tanaka
Minoru Yoshida
Sueharu Horinouchi
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Application granted granted Critical
Publication of ATE425177T1 publication Critical patent/ATE425177T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Glass Compositions (AREA)
  • Materials For Medical Uses (AREA)
AT01947940T 2000-07-17 2001-07-09 Reduziertes fk228 und seine verwendung ATE425177T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000216584 2000-07-17

Publications (1)

Publication Number Publication Date
ATE425177T1 true ATE425177T1 (de) 2009-03-15

Family

ID=18711825

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01947940T ATE425177T1 (de) 2000-07-17 2001-07-09 Reduziertes fk228 und seine verwendung

Country Status (7)

Country Link
US (1) US7056884B2 (de)
EP (1) EP1302476B1 (de)
JP (1) JP4810784B2 (de)
AT (1) ATE425177T1 (de)
DE (1) DE60137932D1 (de)
ES (1) ES2321584T3 (de)
WO (1) WO2002006307A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7396665B2 (en) 2000-09-01 2008-07-08 Astellas Pharma, Inc. Method of producing FR901228
RU2298414C2 (ru) * 2001-08-21 2007-05-10 Астеллас Фарма Инк. Медицинское применение ингибитора гистоновой дезацетилазы и способ оценки его противоопухолевого действия
US7566535B2 (en) 2002-03-07 2009-07-28 University Of Delaware Enhanced oligonucleotide-mediated nucleic acid sequence alteration
EP1492596A1 (de) * 2002-04-05 2005-01-05 Fujisawa Pharmaceutical Co., Ltd. Depsipeptid zur behandlung von nierenkrebs
CA2495354A1 (en) * 2002-08-20 2004-03-04 Yamanouchi Pharmaceutical Co., Ltd. An agent for inhibiting articular cartilage extracellular matrix degradation
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2004074478A1 (ja) * 2003-02-19 2004-09-02 Astellas Pharma Inc. ヒストンデアセチラーゼ阻害剤の抗腫瘍効果の予測方法
US7375228B2 (en) 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1491188A1 (de) * 2003-06-25 2004-12-29 G2M Cancer Drugs AG Topische Verwendung von Valproinsäure zur Behandlung von Hauterkrankungen
EP1638541B1 (de) 2003-06-27 2010-05-19 Astellas Pharma Inc. Therapeutisches mittel für ein weichteilsarkom
DE602004027824D1 (de) 2003-09-25 2010-08-05 Astellas Pharma Inc Antitumorales mittel mit einem histon-deacetylase-hemmer und einem topoisomerase-ii-hemmer
WO2005058298A2 (en) * 2003-12-10 2005-06-30 Wisconsin Alumni Research Foundation Fk228 analogs and their use as hdac-inhibitors
US20050137234A1 (en) * 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
WO2005065681A1 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
US7951780B2 (en) 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
US20050187148A1 (en) * 2004-02-25 2005-08-25 Yoshinori Naoe Antitumor agent
WO2006055621A2 (en) * 2004-11-17 2006-05-26 The University Of Chicago Histone deacetylase inhibitors and methods of use
US7642275B2 (en) * 2004-12-16 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP2008540574A (ja) 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
GB0511266D0 (en) * 2005-06-02 2005-07-13 Trust Chemical compounds
CA2615105A1 (en) * 2005-07-14 2007-01-25 Takeda San Diego, Inc. Histone deacetylase inhibitors
CA2630216A1 (en) * 2005-11-18 2007-05-31 Gloucester Pharmaceuticals, Inc. Metabolite derivatives of the hdac inhibitor fk228
EP1976835A2 (de) * 2006-01-13 2008-10-08 Takeda San Diego, Inc. Histondeacetylase-inhibitoren
US9539303B2 (en) 2006-04-24 2017-01-10 Celgene Corporation Treatment of Ras-expressing tumors
US8957027B2 (en) 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
CA2670223A1 (en) * 2006-11-22 2008-05-29 Karus Therapeutics Limited Depsipeptides and their therapeutic use
CN103497238A (zh) * 2006-12-29 2014-01-08 细胞基因公司 制备Romidepsin
EP2102230A2 (de) * 2006-12-29 2009-09-23 Gloucester Pharmaceuticals, Inc. Reinigung von romidepsin
JP2012506428A (ja) * 2008-10-24 2012-03-15 グルオウセステル プハルマセウトイカルス ガンの療法
CN103108648A (zh) 2010-07-12 2013-05-15 细胞基因公司 罗米地辛固体形式及其用途
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
US20150174235A1 (en) * 2012-06-06 2015-06-25 Bionor Immuno As Vaccine
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
CN104450837B (zh) * 2013-09-18 2019-01-01 上海医药工业研究院 一种用于生产罗米地辛的方法及发酵培养基
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
CN109796521B (zh) * 2017-11-17 2022-04-19 上海医药工业研究院 一种罗米地辛醋酸盐晶型及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8817743D0 (en) * 1988-07-26 1988-09-01 Fujisawa Pharmaceutical Co Fr901228 substance & preparation thereof
CA2149038C (en) 1993-09-10 2000-06-13 Motoo Yamasaki Phospholipase c-inhibiting peptides

Also Published As

Publication number Publication date
US7056884B2 (en) 2006-06-06
WO2002006307A1 (en) 2002-01-24
DE60137932D1 (de) 2009-04-23
EP1302476B1 (de) 2009-03-11
EP1302476A1 (de) 2003-04-16
JP4810784B2 (ja) 2011-11-09
EP1302476A4 (de) 2006-06-28
US20040053820A1 (en) 2004-03-18
ES2321584T3 (es) 2009-06-09

Similar Documents

Publication Publication Date Title
DE60137932D1 (de) Reduziertes fk228 und seine verwendung
ATE388951T1 (de) Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
BRPI0409227B8 (pt) "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)"
BG106020A (en) Inhibitors of impdh enzyme
BR9910849A (pt) Composto, processo para a profilaxia ou tratamento de uma condição clìnica em um mamìfero, tal como um humano, formulação farmacêutica, uso de um composto, processo para preparação do composto, e, derivado protegido.
PL369078A1 (en) Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia
ATE303993T1 (de) 4-hydroxychinolin-3-carboxamide und hydrazide als antivirale wirkstoffe
BR0212510A (pt) Inibidor de histona desacetilase, composto e composição
ATE399012T1 (de) Carbaminsäurederivate enthaltend eine piperazin verknüpfung als hdac-inhibitoren
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
SI1780197T1 (sl) 5-substituirani-2-fenilamino benzamidi kot mek-inhibitorji
ATE353319T1 (de) Acetylenderivate als inhibitoren von histondeacetylase
AU2002342878A1 (en) Pyridylpyrimidine derivatives as effective compounds against prion diseases
DE69811111D1 (de) Hydroxamsäure- und carbonsäurederivate mit mmp und tnf hemmender wirkung
ATE448194T1 (de) Verwendung einer pharmazeutischen zusammensetzung mit einem para-aminophenylessigsäurederivat für die behandlung von entzündlichen erkrankungen des magen-darmtrakts
IL164767A0 (en) 7-Aryl-3,9-diazabicyclo (3.3.1) non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertenision, cardiovascular or renal diseases
DE602004014791D1 (de) Zur behandlung von schmerzen geeignete phenylcarbonsäureamidverbindungen
NO20025810D0 (no) Faktor VIIA-inhibitoriske (tio)ureaderivater, deres fremstilling og anvendelse
TNSN04203A1 (en) Benzoxazinone-derived compounds, their preparation and use as medicaments
LV12291A (lv) Savienojums un farmaceitiskas kompozicijas ar triptazes aktivitates izmainam saistitu slimibu arstesanai
IL123805A0 (en) Use of hydroximic acid derivatives for the protection of mitochondrial genome
BR0311136A (pt) composto ou um sal, enanciÈmero, diaestereÈmero ou éster hidrolisável in vivo ou mistura dos mesmos farmaceuticamente aceitável, composição, e, método para inibir a atividade de fator letal (lf) liberado de bactérias em um mamìfero
ATE326964T1 (de) Aminosäurederivate zur behandlung der alzheimer- krankheit
DE69914614D1 (de) Ungesättigte hydroximsäurederivate als parp inhibitoren
RU95110774A (ru) Олигонуклеотиды, терапевтические композиции, применение композиций

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1302476

Country of ref document: EP